Clinical Trial

We Analyse Metabolites in Dried Blood Spots From Newborns That Later in Life Developed an Eating Disorder.

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Anorexia nervosa (AN) and bulimia nervosa (BN) are serious eating disorders (EDs) with significant morbidity and mortality. Genetic studies have shown associations between EDs and metabolic traits, and longitudinal studies indicate distinct weight trajectories in children who later develop AN or BN, suggesting early involvement of metabolic factors. Biological studies also reveal differences in immune and neurotrophic markers in individuals with EDs compared to controls. Intriguingly, metabolites measured in neonatal blood could serve as very early markers of ED risk, unconfounded by state or scar factors related to prolonged starvation. Here the investigators propose to comprehensively analyze neonatal biomarkers (metabolic, immune, and neurotrophic), epidemiological factors, and genetics to understand ED risk and develop risk prediction models
Trial Details
NCT Number NCT07016334
Lead Sponsor Karolinska Institutet
Conditions Eating Disorders
Enrollment 3,000 participants
Start Date 2022-09-01
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-06-11